Abstract

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma
Thomas A Buchholz ... Miguel A Canales
Blood | VOL. 134
Thomas A Buchholz, et. al.Thomas A Buchholz ... Miguel A Canales
13 Nov 2019
Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma
Miguel Canales ... Shinya Rai
Blood | VOL. 138
Miguel Canales, et. al.Miguel Canales ... Shinya Rai
05 Nov 2021
Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.
Kai Hübel ... Ekaterina Vorozheikina
Journal of Clinical Oncology | VOL. 39
Kai Hübel, et. al.Kai Hübel ... Ekaterina Vorozheikina
20 May 2021
Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial
Tina Nielsen ... Franck Morschhauser
Blood | VOL. 132
Tina Nielsen, et. al.Tina Nielsen ... Franck Morschhauser
29 Nov 2018
View more papers

More From: HemaSphere

Paper Title
Journal
Date
Author
An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome-like acute lymphoblastic leukemia.
Zicong Huang ... Hongsheng Zhou
HemaSphere | VOL. 8
Zicong Huang, et. al.Zicong Huang ... Hongsheng Zhou
01 May 2024
Interplay between α-thalassemia and β-hemoglobinopathies: Translating genotype-phenotype relationships into therapies.
Jim Vadolas ... George Grigoriadis
HemaSphere | VOL. 8
Jim Vadolas, et. al.Jim Vadolas ... George Grigoriadis
01 May 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Fabio Efficace ... Amer M Zeidan
HemaSphere | VOL. 8
Fabio Efficace, et. al.Fabio Efficace ... Amer M Zeidan
01 May 2024
-
-
HemaSphere | VOL. 8
--
01 May 2024
View more papers